Genetics of platelet glycoprotein receptors: Risk of thrombotic events and pharmacogenetic implications

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 2, 2005, Pages 113-125

  Mikkelsson, Jussi ^a   Perola, Markus ^b   Karhunen, Pekka J ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b NONE

Author keywords

Genetics; Myocardial infarction; Pharmacogenetics; Platelets; Polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2 INTEGRIN; BETA1 INTEGRIN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIIA;

ATHEROSCLEROSIS; CAUCASIAN; CORONARY ARTERY THROMBOSIS; DRUG RESISTANCE; FATALITY; GENETIC VARIABILITY; HEART INFARCTION; HETEROZYGOTE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VARIABLE NUMBER OF TANDEM REPEAT;

HUMANS; MYOCARDIAL INFARCTION; PHARMACOGENETICS; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; THROMBOSIS;

EID: 17444395183     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100201     Document Type: Review

References (145)

1. Norris RM. The natural history of acute myocardial infarction. Heart 2000;83:726.
2. Braunwald E. Shattuck lecture: Cardiovascular medicine at the turn of the millenium: Triumphs, concerns and opportunities. N Engl J Med 1997;337:1360.
3. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898.
4. Rentrop KP. Thrombi in acute coronary syndromes. Revisited and revised. Circulation 2000;101:1619.
5. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101:1206.
6. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996;348:1329.
7. The CURE investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494.
8. Kiss RG, Kerecsen G, Bato Z, et al. Aspirin resistance is associated with platelet GP IIb/IIIa receptor polymorphism PlA2 and thrombotic events in coronary heart disease patients undergoing percutaneous coronary procedures. Eur Heart J 2000;21(Suppl Aug/Sept):648.
9. Trip MD, Jukema JW, Zwinderman AH, et al. The platelet GPIIIa PlA polymorphism, premature coronary artery disease, progression of disease and response to aspirin. Circulation 1999;100 (suppl. I).
10. Poggio ED, Kottke-Marchant K, Welsh PA, et al. The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100. J Am Coll Cardiol 1999;33:254A.
11. Tarjan J, Salomon A, Jager R, et al. The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis. Orv Hetil 1999; 140:2339.
12. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230.
13. Topol EJ. The future of antiplatelet therapy: Optimizing management in patients with acute coronary syndrome. Clin Cardiol 2000;23(suppl. 6):VI-23.
14. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650.
15. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961.
16. Lepantalo A, Virtanen K, Wartiovaara U, Lassila R. Limited antiplatelet effect of combining ASA and clopidogrel in patients undergoing elective PTCA. Thromb Haemost 2001;(suppl.):OC2393.
17. Wu KK, Willerson JT. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy. Circulation 2001; 103:2528.
18. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively. A determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001;104:181.
19. Braunwald E. Management of unstable angina based on considerations of aetiology. Heart 1999;82 (suppl. I):15.
20. Yokoya K, Takatsu H, Suzuki T, et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis. Circulation 1999;100:903.
21. Murphy JJ, Connell PA. Prodromal chest pains: Clues to the pathogenesis of non-Q wave acute myocardial infarction? Int J Cardiol 1992;37:188.
22. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998;98:2334.
23. Choudhury L, Marsh JD. Myocardial infarction in young patients. Am J Med 1999;107:254.
24. Fuster V, Badimon JJ, Badimon L, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (Part II). N Engl J Med 1992; 326:310.
25. Rosenfeld SJ, Gralnick HR. Adhesive interactions in hemostasis. Acta Haematol 1997;97:118.
26. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces thrombogenicity of disrupted human atherosclerotic plaques. Effects of tissue factor pathway inhibitor on plaque inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999;99:1780.
27. Scarabin P-Y, Aillaud MF, Amouyel P, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. Thromb Haemost 1998;80:749.
28. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165.
29. Wiman B. Plasminogen activator inhibitor 1 in thrombotic disease. Curr Opin Hematol 1996;3:372.
30. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115.
31. Koukkunen H, Penttila K, Kemppainen A, et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37.
32. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 1998;3:199.
33. Beer JH, Pederiva S, Pontiggia L. Genetics of platelet receptor single-nucleotide polymorphisms: Clinical implications in thrombosis. Ann Med 2000;32(Suppl 1):10-4. Review.
34. Marenberg ME, Risch N, Berkman LF, et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041.
35. Rissanen AM. Familial occurrence of coronary heart disease: Effect of age at diagnosis. Am J Cardiol 1979;44:60.
36. Colditz GA, Rimm EB, Giovannucci E, et al. A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol 1991; 67:933.
37. Ciruzzi M, Schargrodsky H, Rozlosnik J, et al. Frequency of family history of acute myocardial infarction in patients with acute myocardial infarction. Am J Cardiol 1997;80:122.
38. Kraus WE. Genetic approaches for the investigation of genes associated with coronary heart disease. Am Heart J 2000;140:S27.
39. Jousilahti P, Puska P, Vartiainen E, et al. Parental history of premature coronary heart disease: An independent risk factor of myocardial infarction. J Clin Epidemiol 1996;49:497.
40. Daly MJ, Rioux JD, Schaffner SF, et al. High resolution haplotype structure in the human genome. Nat Genet 2001;29:229.
41. Gillum RF. Sudden coronary death in the United States: 1980-85. Circulation 1989;79:756.
42. de Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990s: A population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997;30:1500.
43. Kannel WB, Thomas HE. Sudden coronary death: The Framingham study. Ann NY Acad Sci 1982;382:3.
44. Sexton PT, Walsh J, Jamrozik K, Parsons R. Risk factors for sudden unexpected cardiac death in Tasmanian men. Aust N Z J Med 1997;27:45.
45. Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: Fatal and non-fatal events. Quart J Med 1994;87:403.
46. Heinrich J, Balleisen L, Schulte H, et al. Fibrinogen and factor VII in the prediction of coronary risk. Arterioscler Thromb 1994;14:54.
47. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism. Arterioscl Thromb Vasc Biol 1999;19:1142.
48. Michelson AD, Furman MI, Goldschmidt-Clermont PJ, et al. Platelet GPIIIa PlA polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013.
49. b) positive platelets in patients with cardiovascular disease. Eur Heart J 1999;20:742.
50. Theodoropoulos I, Christopoulos C, Metcalfe P, et al. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. Br J Haematol 2001;114:387.
51. Meiklejohn DJ, Vickers MA, Morrison ER, et al. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001;112:621.
52. Carlsson LE, Grossjohann B, Freier J, et al. The impact of GPIIb-IIIa and GPIa-IIa polymorphisms in the adhesion of platelets to collagen and fibrinogen in a microtiter-plate adhesion system under static and dynamic conditions. XIX Congress of the International Society of Thrombosis and Haemostasis 2003 meeting abstract.
53. Frey UH, Aral N, Muller N, Siffert W. Cooperative effect of GNB3 825 C>T and GPIIIa Pl(A) polymorphisms in enhanced platelet aggregation. Thromb Res 2003;109:279.
54. Honda S, Honda Y, Bauer B, et al. The impact of three-dimensional structure on the expression of PlA alloantigens on human integrin β3. Blood 1995;86:234.
55. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The Pl(A2) polymorphism of intgerin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000;105:793.
56. Vijayan KV, Liu Y, Dong JF, Bray PF. Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro33 polymorphism of integrin beta 3. J Biol Chem 2003;278:3860.
57. Vijayan KV, Huang TC, Liu Y, et al. Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS Lett 2003;540:41.
58. Sajid M, Vijayan KV, Souza S, Bray PF. PlA polymorphism of integrin beta3 differentially modulates cellular migration on extracellular matrix proteins. Arterioscler Thromb Vasc Biol 2002;22:1984.
59. Szczeklik A, Undas A, Sanak M, et al. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000;110:965.
60. Bennett JS, Catella-Lawson F, Rut AR, et al. Effect of the PlA2 alloantigen on the function of β3-integrins in platelets. Blood 2001;97:3093.
61. Boval B, Gueguen R, Mazoyer E, et al. Lack of correlation between HPA-1 polymorphism and ADP induced platelet activation: Study of a large cohort of normal subjects. XIX Congress of the International Society of Thrombosis and Haemostasis 2003 meeting abstract.
62. Feng D, Lindpaintner K, Larson MG, et al. Platelet glycoprotein IIIa PlA polymorphism, fibrinogen, and platelet aggregability. Circulation 2001;104:140.
63. Kaski S, Kekomaki R, Partanen J. Systematic screening for genetic polymorphism in human platelet glycoprotein Ibα. Immunogenetics 1996;44:170.
64. Corral J, Gonzalez-Conejero R, Lozano ML, et al. New alleles of the platelet glycoprotein Ibalpha gene. Br J Haematol 1998;103:997.
65. Li CQ, Garner SF, Davies J, et al. Threonine-145/Methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbalpha express HPA-2 epitopes and show equal binding of von willebrand factor. Blood 2000;95:205.
66. Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, et al. Von willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vasc Biol 2003; 23:1302.
67. Douglas H, Gorog D, Ahmed N, et al. Functional significance of GPIb alpha receptor polymorphism in patients with coronary artery disease. Eur Heart J 2000;21 (suppl Aug/Sept):66.
68. Cadroy Y, Sakariassen KS, Charlet J-P, et al. Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood. 2001;98:3159.
69. Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, López JA. Kozak sequence polymorphism of the glycoprotein (GP) Ibα gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. Blood. 1999;94:186.
70. Corral J, Lozano ML, González-Conejero R, et al. A common polymorphism flanking the atg initiator codon of GPIbα does not affect expression and is not a major risk factor for arterial thrombosis. Thromb Haemost 2000;83:23.
71. Macchi L, Sorel N, Brabant S, et al. Relationship between C-5T Kozak, C807T genotypes and expression of glycoproteins Ibα and Ia-IIa at platelet surface: From genotype to phenotype. Thromb Haemost 2002;88:368.
72. Corral J, Gonzalez-Conejero R, Rivera J, et al. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function-effect in thromboembolic diseases. Thromb Haemost 1999;81:951.
73. Kritzik M, Savage B, Nugent DJ, et al. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2beta1 density. Blood 1998;92:2382.
74. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood 1993;82:2693.
75. Jacquelin B, Tarantino MD, Kritzik M, et al. Allele-dependent transcriptional regulation of the human integrin alpha(2) gene. Blood 2001;97:1721.
76. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PlA1/PlA2 and coronary risk: A meta-analysis. Thromb Haemost 2001;85:626.
77. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol 2000; 86:1000.
78. Wu AHB, Tsongalis GJ. Correlation of polymorphisms to coagulation biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001;87:1361.
79. Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Statist Med 2003;22:1741.
80. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000;7:284.
81. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999;94:46.
82. Benze G, Heinrich J, Schulte H, et al. Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J 2002;23:325.
83. Ripoll L, Collet JP, Mazoyer E, et al. PlA GPIIIa platelet polymorphism is a genetic risk factor for myocardial infarction in patients under 45. Thromb Haemost 2001; (suppl.):P1181.
84. Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bb 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997;96:1424.
85. Schwartz E, Demidova D, Sirotkina O, Kudinov S. The combination of glycoprotein IIIa PlA polymorphism with polymorphism of serotonin transporter as an independent strong risk factor for the occurrence of coronary thrombosis. Mol Genet Metab 2003;79:229.
86. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003;107:1117.
87. Mikkelsson J, Perola M, Laippala P, et al. Glycoprotein UIa PlA1/A2 polymorphism and sudden cardiac death. J Am Coll Cardiol 2000;36:1317.
88. Burke AP, Creighton W, Malcom G, et al. Platelet gpIIIa polymorphism is a risk factor for sudden coronary death. Circulation 1999;100 (Suppl 1):776.
89. Auguardo C, Specchia G, Priori SG. Prognostic value of GPIIb/IIIa polymorphism in patients with acute myocardial infarction. Eur Heart J 2001;(Suppl):150.
90. Bojesen SE, Juul K, Schnohr P, et al. Platelet glycoprotein IIb/IIIa PlA2/A2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men. J Am Coll Cardiol 2003;42:661.
91. Zotz RB, Mueller C, Nitz W, et al. Platelet GPIIIa T1565C (HPA-1B/PLA2) and GPIa 807TT are risk determinants for platelet thrombogenicity. Br J Haematol 2000; 111(suppl. I)A74.
92. Anderson JL, King GJ, Bair TL, et al. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol 1999;33:727.
93. Zotz RB, Winkelmann BR, Nauck M, et al. Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998;79:731.
94. Bray PF, Cannon C, Goldschmidt-Clermont P, et al. The platelet PlA2 and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88:347.
95. Brscic E, Bergerone S, Gagnor A, et al. Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J 2000;139:979.
96. Walter DH, Schachinger V, Elsner M, et al. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997;350:1217.
97. Mehilli J, Kastrati A, Koch W, et al. Patients homozygous for the PlA2 allele coding for platelet glycoprotein IIIa are at an increased risk for stent vessel thrombosis. Circulation 1999;18(Suppl I):288.
98. Kastrati A, Schomig A, Seyfarth M, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99:1005.
99. Kastrati A, Koch W, Gawaz M, et al. PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol 2000;36:84.
100. Walter DH, Goette S, Auch-Schwelk W, Elsner M. Aggressive antiplatelet therapy reduces the risk of coronary stent thrombosis associated with the GPIIb/IIIa PLA2 polymorphism. Circulation 1999;18(Suppl I):709.
101. Sydor WJ, Dudek D, Sanak M, et al. Prognostic value of selected genetic variants of platelet glycoprotein receptors in prediction of thrombotic events after percutaneous coronary interventions. XIX Congress of the International Society of Thrombosis and Haemostasis 2003 meeting abstract.
102. Zotz RB, Klein M, Dauben HP, et al. Prospective analysis after coronary-artery bypass grafting: Platelet GP IIIa polymorphism (HPA-1b/PlA2) is a risk factor for bypass occlusion, myocardial infarction, and death. Thromb Haemost 2000;83:404.
103. Rinder CS, Mathew JP, Rinder HM, et al. Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. Anesthesiology 2002;97:1118.
104. Cooke GE, Bray PF, Hamlington JD, et al. PlA2 polymorphism and the efficacy of aspirin. Lancet 1998;351:1253.
105. Macchi L, Christiaens, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003;42:1115.
106. Undas A, Sanak M, Musial J, et al. Platelet glycoprotein IIIa polymorphism, aspirin and thrombin generation. Lancet 1999;353:982.
107. Undas A, Brummel K, Musial J, et al. PlA2 polymorphism of beta3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666.
108. Goldschmidt-Clermont PJ, Roos CM, Cooke GE. Platelet PlA2 polymorphism and thromboembolic events: From inherited risk to pharmacogenetics. J Thromb Thrombotysis 1999;8:89.
109. Dropinski J, Brzeziska-Kolarz B, Wgrzyn W, et al. Platelet glycoprotein IIIa polymorphism and antithrombotic actions of aspirin and clopidogrel in atherosclerosis. Thromb Haemost 2001;(suppl.):P1881.
110. Weber AA, Jacobs C, Meila D, et al. No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics 2002;12:581.
111. Gonzalez-Conejero R, Lozano ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Ib alpha associated with arterial thrombotic disease. Blood 1998;92:2771.
112. Rosenberg N, Zivelin A, Chetrit A, et al. Effects of platelet membrane glycoprotein polymorphisms on the risk of myocardial infarction in young males. Isr Med Assoc J 2002;4:411.
113. Mercier B, Munier S, Bertault V, et al. Myocardial infarction: Absence of association with VNTR polymorphism of GP Ibalpha. Thromb Haemost 2000;84:921.
114. Mikkelsson J, Perola M, Penttila A, Karhunen PJ. Platelet GP Ibα HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 2001;104:876.
115. Santoso S, Zimmermann P, Sachs UJH, Gardemann A. The impact of the Kozak sequence polymorphism of the glycoprotein Ibα gene on the risk and extent of coronary heart disease. Thromb Haemost 2002;87:345.
116. Meisel C, Afshar-Kharghan V, Cascorbi I, et al. Role of Kozak sequence polymorphism of platelet glycoprotein Ibα as a risk factor for coronary artery disease and catheter interventions. J Am Coll Cardiol 2001;38:1023.
117. Kenny D, Muckian C, Fitzgerald DJ, et al. Platelet glycoprotein ibalpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombotysis 2002;13:13.
118. Moshfegh K, Redondo M, Wuillemin WA, et al. Kozak sequence polymorphism of platelet adhesion receptor GPIbα gene related to variation in receptor density is associated with myocardial infarction. Eur Heart J 2000;21(Suppl.):130.
119. Croft SA, Hampton KK, Daly ME, et al. Kozak sequence polymorphism in the platelet GPIba gene is not associated with risk of myocardial infarction. Blood 2000;95:2183.
120. Douglas H, Michaelides K, Gorog DA, et al. Platelet membrane glycoprotein Ibα gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart 2002;87:70.
121. Ishida F, Ito T, Takei M, et al. Genetic linkage of Kozak sequence polymorphism of the platelet glycoprotein Ibα with human platelet antigen-2 and variable number of tandem repeats polymorphism, and its relationship with coronary artery disease. Br J Haematol 2000;111:1247.
122. Santoso S, Kunicki TJ, Kroll H, et al. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999;93:2449.
123. Corral J, Gonzalez-Conejero R, Rivera J, et al. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function. Thromb Haemost 1999;81:951.
124. Croft SA, Hampton KK, Sorrell JA, et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999;106:771.
125. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study. Lancet 1998;353:351.
126. Kroll H, Gardemann A, Fechter A, et al. The impact of the glycoprotein Ia collagen receptor subunit A1648G gene polymorphism on coronary artery disease and acute myocardial infarction. Thromb Haemost 2000;83:392.
127. Morita H, Kurihara H, Imai Y, et al. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and myocardial infarction in Japanese. Thromb Haemost 2001;85:226.
128. Casorelli I, De Stefano V, Leone AM, et al. The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001;114:150.
129. Singh RK, Patel H, Braund P, et al. Platelet glycoprotein Ia polymorphism and expression in young myocardial infarction patients and controls. Eur Heart J 2001; Suppl:121.
130. Von Beckerath N, Koch W, Mehilli J, et al. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood 2000;95:3297.
131. Von Beckerath N, Koch W, Mehilli J, et al. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. Atherosclerosis 2001;156:463.
132. Mikkelsson J, Penttila A, Karhunen PJ. Platelet collagen receptor GPIa (C807T/HPA-5) haplotype is not associated with an increased risk of fatal coronary events in middle aged men. Arterioscler Thromb Vasc Biol 2001; 21:682.
133. 1 is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000;102:1645.
134. Ikeda Y, Handa M, Murata M, Goto S. A new approach to antiplatelet therapy: Inhibitor of GPIb/V/IX-vWF interaction. Haemostasia 2000;30(Suppl 3):44.
135. Yeh CH, Chang MC, Peng HC, Huang TF. Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. Br J Pharmacol 2001;132:843.
136. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1974;1:436.
137. Breddin K, Loew D, Lechner K, et al. The German-Austrian aspirin trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980;62:V63.
138. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101:1206.
139. Furberg CD. Secondary prevention trials after acute myocardial infarction. Am J Cardiol 1987;60:28A.
140. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979;2:1313.
141. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Br Med J 1994;308:81.
142. King SB 3rd. Optimizing antiplatelet therapy in coronary interventions. Clin Cardiol 2000;23(Suppl 6):VI-8.
143. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary interventions: The PCI-CURE study. Lancet 2001; 358:527.
144. Dangas G, Colombo A. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. Am Heart J 1999;138(1 Pt 2):S16.
145. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78(3A):35.